Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than comprehensive financial performance.
Material Changes
A re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan resulted in an increase in the notional allocation of Ordinary share ADRs on February 19, 2010. The transaction price was $38.26 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: February 19, 2010 (Notification date: February 22, 2010).
- Transaction Price: $38.26 per ADR.
- Participants: Dr M M Slaoui (16 shares), Ms D Connelly (14 shares), Mr W C Louv (8 shares), Dr D Pulman (12 shares).
- Context: The increase in allocation was due to a re-valuation of the cash element within the US Retirement Savings Plan.